RT Journal Article
SR Electronic
T1 Pharmacology study of the neutral myocardial imaging agent technetium-99m-N(NOEt)2.
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 54
OP 56
VO 27
IS 1
A1 Fang, P
A1 Wang, B C
A1 Wu, C Y
A1 Wan, W X
A1 Jiang, N Y
A1 Zhou, X
A1 Chen, Z P
YR 1999
UL http://tech.snmjournals.org/content/27/1/54.abstract
AB The biological properties of a new neutral myocardial imaging agent 99mTcN(NOEt)2 were evaluated.Blood clearance in rabbits, biodistribution in rats, and initial myocardial imaging in dogs were performed.Radiochemical purity of 99mTcN(NOEt)2 was more than 90% and stable for 6 h at room temperature. Blood disappearance was analyzed with a biexponential model and T1/2(alpha) = 2.53 min, T1/2(beta) = 330 min and CI = 378 ml/h were obtained. Biodistribution studies demonstrated that 99mTcN(NOEt)2 localized selectively in the rat myocardium. Cardiac uptakes were 4.69, 4.20, 3.95 and 3.43% ID/g at 5, 30, 60 and 90 min postinjection, respectively. The mean heart-to-lung activity ratios were 1.69, 2.40 and 2.55 at 10 min, 30 min and 60 min postinjection, respectively.Technetium-99m-N(NOEt)2 exhibited favorable stability and biological properties. Further study in humans is required.